GENERIC SWITCH EVALUATION OF CELEBREX® IN PATIENTS WITH OSTEOARTHRITIS (OA) USING A RETROSPECTIVE CLAIMS DATABASE
Author(s)
JI X1, Liu S1, Solem CT1, Shelbaya A2, Walker C3, Cappelleri JC4, Gao X1, Stephens JM1
1Pharmerit International, Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA, 3Pfizer, Inc, Tadworth, Surrey, UK, 4Pfizer Inc, Groton, CT, USA
OBJECTIVES: The full economic impact of brand to generic switching within OA has not been well studied. The purpose of this study was to measure switch rates from the branded COX-2 inhibitor Celebrex (celecoxib) to generic non-steroidal anti-inflammatory drugs (NSAIDs) and compare economic outcomes between switched and persistent patients with OA. METHODS: This retrospective claims analysis used MarketScan®
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PMS31
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Musculoskeletal Disorders, Systemic Disorders/Conditions